Deal Watch: Pfizer Lays Groundwork In Gene Therapy

Pfizer expands its position in rare diseases in a collaboration with Spark Therapeutics and also licenses a pair of preclinical oncology candidates from Belgium’s iTeos Therapeutics. Meanwhile, Shire gets $15 million in research funding from the Cystic Fibrosis Foundation to help advance a novel aerosolized therapy addressing the underlying cause of CF.